Richard A. Stein. Genetic Engineering & Biotechnology News. 2017.
An advantage of the LODER platform is that it delivers RNAi locally, within the tumor, Circumventing systemic toxicity and the need for large systemically administered doses.
“We have preclinical and clinical data showing that our treatment is safe,” asserts Dr. Shemi. “It affects the development of tumors and impedes the development of new metastases.”
Unpublished preclinical studies show that Loder may be used in combination with immune-oncology treatments. “We strongly believe that this combination can open new markets for many companies for treating pancreatic cancer and possibly other solid tumors,” comments Dr. Shemi.